WO1999020742A3 - Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv - Google Patents

Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv Download PDF

Info

Publication number
WO1999020742A3
WO1999020742A3 PCT/EP1998/006610 EP9806610W WO9920742A3 WO 1999020742 A3 WO1999020742 A3 WO 1999020742A3 EP 9806610 W EP9806610 W EP 9806610W WO 9920742 A3 WO9920742 A3 WO 9920742A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell line
packaging cell
line producing
mlv
siv
Prior art date
Application number
PCT/EP1998/006610
Other languages
English (en)
Other versions
WO1999020742A2 (fr
Inventor
Stefano Indraccolo
Fabrizio Mammano
Original Assignee
Univ Padova
Stefano Indraccolo
Fabrizio Mammano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Padova, Stefano Indraccolo, Fabrizio Mammano filed Critical Univ Padova
Priority to AU13349/99A priority Critical patent/AU1334999A/en
Priority to EP98956852A priority patent/EP1025208A2/fr
Publication of WO1999020742A2 publication Critical patent/WO1999020742A2/fr
Publication of WO1999020742A3 publication Critical patent/WO1999020742A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une lignée de cellules d'encapsidation encapsidant le génome à base MLV d'un rétrovirus de recombinaison en une particule à enveloppe SIV, et une particule de rétrovirus pseudo typée par la lignée de cellules d'encapsidation. La lignée de cellules d'encapsidation ainsi que la particule de rétrovirus lorsqu'elles comportent des gènes thérapeutiques s'avèrent particulièrement utiles pour la thérapie par des gènes somatiques notamment chez les mammifères dont l'homme.
PCT/EP1998/006610 1997-10-20 1998-10-19 Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv WO1999020742A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU13349/99A AU1334999A (en) 1997-10-20 1998-10-19 A packaging cell line producing siv-pseudotyped mlv
EP98956852A EP1025208A2 (fr) 1997-10-20 1998-10-19 Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK1196/97 1997-10-20
DK119697 1997-10-20

Publications (2)

Publication Number Publication Date
WO1999020742A2 WO1999020742A2 (fr) 1999-04-29
WO1999020742A3 true WO1999020742A3 (fr) 1999-07-01

Family

ID=8102058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006610 WO1999020742A2 (fr) 1997-10-20 1998-10-19 Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv

Country Status (3)

Country Link
EP (1) EP1025208A2 (fr)
AU (1) AU1334999A (fr)
WO (1) WO1999020742A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0817858B1 (fr) 1995-03-09 2003-04-23 Austrian Nordic Biotherapeutics AG Vecteurs qui portent des genes therapeutiques codant des peptides antimicrobiens pour la therapie genique
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
AU2002218218A1 (en) * 2000-10-10 2002-04-22 Austrian Nordic Biotherapeutics Ag A novel system for the evaluation of the activity and/or specificity of a viral component
WO2008151633A2 (fr) * 2007-06-15 2008-12-18 Skau Aps Vecteurs pour un vaccin contre le vih-1
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
CA2816570A1 (fr) 2010-10-31 2012-05-03 Tocagen Inc. Traitement et surveillance ameliores du cancer au moyen de vecteurs recombinants
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011524A1 (fr) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Particules vectorielles pouvant etre ciblees
WO1997017457A2 (fr) * 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Lignees cellulaires stables d'encapsidation produisant un retrovirus pseudotype
WO1998038325A2 (fr) * 1997-02-27 1998-09-03 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011524A1 (fr) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Particules vectorielles pouvant etre ciblees
WO1997017457A2 (fr) * 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Lignees cellulaires stables d'encapsidation produisant un retrovirus pseudotype
WO1998038325A2 (fr) * 1997-02-27 1998-09-03 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C.P. SPIES ET AL.,: "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain", JOURNAL OF VIROLOGY, vol. 68, no. 2, 1994, pages 585 - 591, XP002101256 *
C.YANG AND R. COMPANS: "Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: Inhibitory effects of the virus-murine leukemia virus envelope proteins: Inhibitory effects of the R peptide", JOURNAL OF VIROLOGY, vol. 70, no. 1, 1996, pages 248 - 254, XP002101006 *
K. ZINGLER AND D.R. LITTMAN: "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity", JOURNAL OF VIROLOGY, vol. 67, no. 5, 1993, pages 2824 - 2831, XP002101007 *
MAMMANO F M ET AL: "TRUNCATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN ALLOWS EFFICIENT PSEUDOTYPING OF MOLONEY MURINE LEUKEMIA VIRUS PARTICLES AND GENE TRANSFER INTO CD4+ CELLS", JOURNAL OF VIROLOGY, vol. 71, no. 4, April 1997 (1997-04-01), pages 3341 - 3345, XP002074198 *
S. INDRACCOLO ET AL.,: "Pseudotyping of Moloney leukemia virus-based retroviral vectors with simian immunodeficiency virus envelope leads to targeted infection of human CD4+ lymphoid cells", GENE THERAPY, vol. 5, no. 2, February 1998 (1998-02-01), pages 209 - 217, XP002101010 *
S. INDRACCOLO ET AL.: "DNA immunization of mice aginst SIVmac293 gag and env using rev-independent expression plasmids", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 1, January 1998 (1998-01-01), pages 83 - 90, XP002101009 *
SCHNIERLE B S ET AL: "PSEUDOTYPING OF MURINE LEUKEMIA VIRUS WITH THE ENVELOPE GLYCOPROTEINS OF HIV GENERATES A RETROVIRAL VECTOR WITH SPECIFICITY OF INFECTION FOR CD4-EXPRESSING CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, August 1997 (1997-08-01), pages 8640 - 8645, XP002074100 *
WILK T ET AL: "RETAINED IN VITRO INFECTIVITY AND CYTOPATHOGENICITY OF HIV-1 DESPITE TRUNCATION OF THE C-TERMINAL TAIL OF THE ENV GENE PRODUCT", VIROLOGY, vol. 189, 1992, pages 167 - 177, XP002074097 *

Also Published As

Publication number Publication date
WO1999020742A2 (fr) 1999-04-29
EP1025208A2 (fr) 2000-08-09
AU1334999A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
WO1992005266A3 (fr) Cellules d'encapsidation
WO1999020742A3 (fr) Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv
CA2223691A1 (fr) Replication du virus de l'herpes simplex specifique de cellule ou de tumeur
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
EP0844888A4 (fr) Vecteurs viraux specifiques a des tissus
EP0979101A4 (fr) ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
WO2003082200A3 (fr) Virus herpes simplex oncolytique puissant pour une therapie du cancer
CA2328404A1 (fr) Nouvelles cellules lentivirales d'encapsidation
WO1996003515A3 (fr) Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1995007995A3 (fr) Liposomes viraux adeno-associes et methodes associees
IL146144A0 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
IL181695A0 (en) Methods for cultivating cells and propagating viruses
KR960001819B1 (en) Viral vector coding for a glycoprotein of the virus responsible
EP1484409A3 (fr) Vecteur d'expression comprenant un gène de résistance aux drogues de courte durée
AU6415496A (en) Encapsulated cells producing viral particles
WO2005038035A3 (fr) Procedes de production et d'utilisation de retrovirus pseudotypes in vivo
WO2001012235A3 (fr) Apport cible de gene artificiel
EP1070122A4 (fr) Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale
EP0801575A4 (fr) Vecteurs retroviraux destines a l'expression dans les cellules embryonnaires
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
AU5008296A (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
CA2282394A1 (fr) Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4
WO2000071078A3 (fr) Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
AU5465899A (en) Pseudotyped retroviruses and stable cell lines for their production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998956852

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998956852

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998956852

Country of ref document: EP